3Guidelines Subcommittee 1999 World Health Organization.International society of hypertension guide lines for the management of hypertension[J].Hypertension,1999,17(5):151-183. 被引量：1
1Pandey MM, Jaipal A, Charde SY, et al. Dissolutionenhancement of felodipine by amorphous nanodispersions usingan amphiphilic polymer: insight into the role of drug-polymerinteractions on drug dissolution [J].Pharm Dev Technol,2015,17(10):10-12. 被引量：1
2Hegazy MA, Fayez YM. Mean centering of ratio spectra andconcentration augmented classical least squares in a comparativeapproach for quantitation of spectrally overlapped bands ofantihypertensives in formulations [J]. Spectrochim Acta A MolBiomol Spectrosc,2015,5(140):210-215. 被引量：1
3Fang H, Chen W, Liu X, et al. The efficacy and safety ofarotinolol combined with a different calcium channel blocker inthe treatment of Chinese patients with essential hypertension: aone-year follow-up study [J]. Clin Exp Hypertens,2014,36(8):590-595. 被引量：1
4Wu Y, Xu M, Wang H, et al. Lercanidipine hydrochloride versusfelodipine sustained-release for mild-to-moderate hypertension: amulti-center, randomized clinical trial [J]. Curr Med Res Opin,2015,31(1):171-176. 被引量：1
5Borghi C, Omboni S. Zofenopril plus hydrochlorothiazidecombination in the treatment of hypertension: an update [J].Expert Rev Cardiovasc Ther,2014,12(9): 1055-1065. 被引量：1
